CEDIRANIB for Papillary thyroid cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 9 adverse event reports in the FDA FAERS database where CEDIRANIB was used for Papillary thyroid cancer.
Most Reported Side Effects for CEDIRANIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 14 | 10.8% | 3 | 8 |
| Fatigue | 13 | 10.0% | 3 | 8 |
| Hypertension | 13 | 10.0% | 0 | 6 |
| Nausea | 8 | 6.2% | 1 | 6 |
| Acute kidney injury | 6 | 4.6% | 2 | 6 |
| Anaemia | 6 | 4.6% | 2 | 2 |
| Colitis | 6 | 4.6% | 1 | 6 |
| Decreased appetite | 6 | 4.6% | 1 | 4 |
| Proteinuria | 6 | 4.6% | 0 | 0 |
| Vomiting | 6 | 4.6% | 1 | 5 |
| Dehydration | 5 | 3.9% | 1 | 4 |
| Disease progression | 5 | 3.9% | 1 | 1 |
| Hyponatraemia | 5 | 3.9% | 2 | 3 |
Other Indications for CEDIRANIB
Ovarian epithelial cancer (19)
Ovarian cancer (16)
Adenocarcinoma of the cervix (5)
Bile duct cancer (5)
Ovarian cancer recurrent (5)
Other Drugs Used for Papillary thyroid cancer
LENVATINIB (501)
DABRAFENIB (98)
SORAFENIB (98)
LEVOTHYROXINE (53)
TRAMETINIB DIMETHYL SULFOXIDE (51)
TRAMETINIB (42)
SODIUM IODIDE I-131 (32)
VEMURAFENIB (26)
CABOZANTINIB S-MALATE (19)
PEMBROLIZUMAB (16)